Heart Failure and Drug Therapies: A Metabolic Review

Area of Science:

• Cardiovascular Research
• Metabolomics
• Pharmacology

Background:

• Cardiovascular disease is a leading global cause of death, with heart failure (HF) affecting millions.
• The heart's high ATP turnover makes cardiac metabolism crucial for maintaining homeostasis.
• Understanding HF pathophysiology is vital for developing effective treatments.

Purpose of the Study:

• To review cardiac metabolism in healthy and failing hearts.
• To explore the role of metabolomics and lipidomics in characterizing HF.
• To discuss the metabolic mechanisms of HF drugs, particularly SGLT2 inhibitors.

Main Methods:

• Review of existing literature on cardiac metabolism and HF.
• Analysis of findings from metabolomics and lipidomics studies in HF.
• Examination of clinical evidence for the metabolic effects of HF therapies.

Main Results:

• -Omic technologies have enhanced the understanding of HF pathologies and identified novel pathways.
• Metabolic alterations are central to the progression of heart failure.
• Sodium-glucose transport protein 2 inhibitors show significant promise, potentially via metabolic actions.

Conclusions:

• Cardiac metabolism is a key area for understanding and treating heart failure.
• Metabolomics and lipidomics provide powerful tools for HF research.
• Targeting metabolic pathways represents a promising therapeutic strategy for HF.